Vismodegib: Indications, Dosing, Side Effects, Practical Guide

Introduction

Basal cell carcinoma (BCC) represents the most common form of skin cancer, typically managed effectively through surgical excision or radiotherapy when confined to localized lesions. However, in rare instances—comprising less than 1% of cases—BCC progresses to an advanced stage, becoming locally advanced or metastatic. Locally advanced BCC invades surrounding tissues, causing significant morbidity, disfigurement, or functional impairment, while metastatic BCC spreads to distant sites such as lymph nodes, lungs, bones, or viscera. These forms render standard treatments like surgery or radiation impractical due to high recurrence risk, substantial deformity, or contraindications.

Vismodegib (Erivedge®, Genentech, Inc.) marks a breakthrough as the first systemic therapy specifically approved for advanced BCC. On January 30, 2012, the US Food and Drug Administration (FDA) granted accelerated approval for adults with metastatic BCC or locally advanced BCC ineligible for surgery or radiation. This oral hedgehog pathway inhibitor targets the underlying molecular driver of BCC pathogenesis, offering tumor regression where conventional options fail. Approval stemmed from the pivotal ERIVANCE BCC phase II trial, demonstrating objective response rates (ORR) of 30-43%.

Indications precisely target:

• Histologically confirmed metastatic BCC.
• Locally advanced BCC recurrent post-radiation or unsuitable for surgery/radiation, with no alternative curative options.

Vismodegib is not indicated for operable BCC, neoadjuvant use, or basal cell naevus syndrome (Gorlin syndrome). Availability varies globally; as of 2016, it lacked funding in New Zealand via PHARMAC, though approvals exist via FDA, EMA, and others. Always consult local datasheets from agencies like FDA, TGA, MHRA, or Medsafe.

How to use

Vismodegib administration is straightforward, enhancing patient adherence in this chronic therapy context. The recommended dose is 150 mg orally once daily, continuous until disease progression or unacceptable toxicity. Capsules must be swallowed whole without opening, crushing, or chewing, ideally with food to minimize gastrointestinal upset though not required.

• Dosing schedule: Take at the same time daily; if missed, skip and resume next scheduled dose—do not double.
• Duration: Indefinite unless progression/toxicity; median treatment in trials ~10 months.
• Monitoring: Monthly clinical exams, labs (liver enzymes, CK, electrolytes), tumor photography, and imaging (MRI/CT) as needed. RECIST 1.1 criteria guide response assessment.
• Discontinuation: Permanent for progression; temporary interruptions (up to 4 weeks) for grade 2+ adverse events, resuming at 150 mg upon resolution.

Patient education emphasizes compliance, toxicity reporting, and contraception due to teratogenicity. Real-world data confirm rapid response (median 1-2 months), with maximum effect by 5-6 months.

How it works

Vismodegib is a first-in-class, selective inhibitor of the Smoothened (SMO) receptor, a key transducer in the Hedgehog (Hh) signaling pathway. Over 90% of BCCs harbor mutations activating Hh, typically loss-of-function in PTCH1 (70-85%) or gain-of-function in SMO (10%). Aberrant Hh activation drives uncontrolled keratinocyte proliferation via GLI transcription factors, unchecked by PTCH1 suppression of SMO.

By competitively binding SMO, vismodegib blocks downstream GLI1/GLI2 activation, halting tumor growth signals. Preclinical models show rapid GLI suppression within hours, translating to clinical regression. Unlike surgery/radiation addressing bulk disease, vismodegib targets microscopic disease, preventing recurrence. Notably, it induces tumor shrinkage (partial response) or complete histological resolution in responsive cases, with durable responses in subsets.

Mechanism summary:

• Hh pathway: Ligand (SHH) binds PTCH1 → SMO activation → GLI nuclear translocation → oncogene expression.
• Vismodegib: SMO antagonist → pathway inhibition → BCC apoptosis/differentiation.

Potential drug interactions

Vismodegib undergoes hepatic metabolism primarily via CYP2C9 and CYP3A4/5, with moderate Tmax (4 hours) and 99% plasma protein binding. Key interactions include:

No significant interactions with radiation or common chemotherapies, but caution with teratogens. P-gp substrates may accumulate.

Adverse events

Vismodegib exhibits a class-effect toxicity profile from Hh inhibition, affecting rapidly dividing tissues (skin, hair, muscle, GI). Over 90% experience events; most grade 1-2, manageable with dose interruption. Dose reductions absent; permanent discontinuation ~20-30%.

Common (≥10%):

• Muscle spasms (70%, median onset 1 month; treat with quinine, stretching, electrolytes)
• Alopecia (60%; reversible)
• Dysgeusia/ageusia (50%; zinc may help)
• Fatigue (40%)
• Nausea/diarrhea (30%)
• Weight loss (median 4-9 kg)
• Alopecia, eyelash growth

Serious/rare: Rhabdomyolysis (CK elevation; monitor), atrial fibrillation, keratoacanthomas (monitor), SJS/TEN, DRESS. ERIVANCE: 75% clinical benefit, but 65% discontinued due to AEs.

Management: Symptomatic; interrupt for grade 3+, resume if resolves to grade 1.

Use in particular populations

Boxed warning: Embryo-fetal toxicity—category X. Causes death/severe defects. Verify pregnancy status before starting.

• Women: Monthly pregnancy tests; contraception during + 24 months post (2 forms: hormonal + barrier).
• Men: Condoms during + 3 months post (semen teratogenic).
• No breastfeeding.

Pediatrics: Safety/efficacy unknown; not approved <18 years.

Elderly: No adjustments; higher toxicity risk.

Renal/hepatic impairment: No dose change (limited data); caution severe cases.

Gorlin syndrome: Effective (phase II data); prevents new BCCs.

Future considerations

Post-approval trials like STEVIE (n=1200+) confirm safety/efficacy in broader populations, with ORR 56-69%, median response 11 months. Ongoing: combinations with radiation/PD-1 inhibitors, neoadjuvant operable BCC, sonidegib (SMO inhibitor analog). Biomarkers (SMO mutations predict resistance). Real-world response 54-86%; no squamous transformation observed.

Challenges: Resistance (SMO mutants), chronic toxicity leading to discontinuation. Pregnancy prevention programs essential. Funded variably; cost-effectiveness improves with generics.

Frequently Asked Questions

What is vismodegib used for?

Treatment of adults with symptomatic metastatic BCC or locally advanced BCC inappropriate for surgery/radiation.

How effective is vismodegib?

ERIVANCE: ORR 43% locally advanced, 30% metastatic; median PFS 9.5 months; 75% clinical benefit.

What are the main side effects?

Muscle spasms, hair loss, taste changes, fatigue, weight loss; mostly reversible.

Is vismodegib safe in pregnancy?

No—absolute contraindication; strict contraception required.

How long to take vismodegib?

Until progression or intolerance; median 7-10 months.

Similar Articles

Alarming Rise in Self-Harm in Young People

Alarming Rise in Self-Harm in Young People

Skin Signs Of Non-Accidental Injury: Expert Guide For Clinicians

Lichen Simplex Of The Scrotum: Diagnosis And Treatment

Labial Adhesion In Prepubertal Girls: What Parents Need To Know

Thrush In Men: 5 Signs, Causes, And Treatment Options

Author

medha deb

 

Medha Deb is an editor with a master's degree in Applied Linguistics from the University of Hyderabad. She believes that her qualification has helped her develop a deep understanding of language and its application in various contexts.

Read full bio of medha deb